Immutrin

Private

UK biotech developing next-generation antibody therapy to reverse ATTR amyloidosis (amyloid cardiomyopathy). Co-founded by Nobel Laureate Sir Gregory Winter. Novel antibody selectively binds amyloid fibrils to stimulate targeted immune-mediated clearance.

Founders Sir Gregory Winter

CEO Sir Gregory Winter

Company

Founded

2023

Headquarters

Cambridge, United Kingdom

Financials

Total Funding

$87M

Sectors

Biotech

www.immutrin.com

Funding History

1 round

Series A Mar 24, 2026

$87M

Frazier Life Sciences (Lead) F-Prime Capital Qiming Venture Partners USA SR One Cambridge Innovation Capital Cambridge Enterprise Ventures

Funding data is compiled from multiple independent sources including company announcements, press coverage, and regulatory filings. While we strive for accuracy, amounts and dates may reflect reported figures at time of announcement.